Short answer
Incyte (INCY) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 8.01 (Other Events). Phase 3 MAESTRA-3 ovarian cancer study canceled before planned fourth-quarter 2026 start.
Incyte 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 3 MAESTRA-3 ovarian cancer study canceled before planned fourth-quarter 2026 start
- INCB123667 development continues without safety or efficacy concerns cited
- Portfolio prioritization shifts resources away from bevacizumab combination maintenance therapy
- No expected impact on financial guidance or previously disclosed long-term outlook
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Incyte 8-K filings
Get the next INCY 8-K as it lands
Follow INCY for push alerts, or ask the research agent what this filing means.